CXCR1 (C-X-C Motif Chemokine Receptor 1), also known as IL-8RA (Interleukin-8 Receptor Alpha), is a G protein-coupled receptor (GPCR) that specifically binds interleukin-8 (IL-8/CXCL8) and granulocyte colony-stimulating factor (G-CSF). Originally characterized for its role in neutrophil recruitment and activation during acute inflammation, CXCR1 is now recognized as a significant contributor to chronic neuroinflammatory processes in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
In the central nervous system (CNS), CXCR1 is expressed on microglia, astrocytes, and neurons, where its activation by IL-8 (produced in response to pathological stimuli) triggers pro-inflammatory signaling cascades that contribute to neuronal dysfunction and death.
| Property |
Value |
| Gene Symbol |
CXCR1 |
| Full Name |
C-X-C Motif Chemokine Receptor 1 |
| Aliases |
IL8RA, IL-8R1, CD128, CD181 |
| Chromosomal Location |
2q35 |
| NCBI Gene ID |
2915 |
| OMIM |
146929 |
| Ensembl ID |
ENSG00000163464 |
| UniProt ID |
P41597 |
| Protein Length |
350 amino acids |
| Molecular Weight |
~40 kDa |
¶ Ligand Binding
CXCR1 is a high-affinity receptor for:
| Ligand |
Chemokine Family |
Signaling |
| CXCL8 (IL-8) |
CXC family |
Primary ligand |
| CXCL6 (GCP-2) |
CXC family |
Alternative ligand |
| CXCL1 (GRO-alpha) |
CXC family |
Lower affinity |
| CXCL7 (NAP-2) |
CXC family |
Lower affinity |
Upon IL-8 binding, CXCR1 activates multiple intracellular signaling cascades:
flowchart TD
A["IL-8/CXCL8"] --> B["CXCR1 Receptor"]
B --> C["Gαi Protein"]
C --> D["PI3K/Akt Pathway"]
C --> E["MAPK/ERK Pathway"]
C --> F["PLC/IP3 Pathway"]
C --> G["β-arrestin Pathway"]
D --> D1["Cell Survival<br/>Migration"]
E --> E1["Proliferation<br/>Inflammation"]
F --> F1["Calcium Release<br/>Degranulation"]
G --> G1["Receptor Desensitization<br/>Signal Termination"]
D1 --> H["Pro-inflammatory Response"]
E1 --> H
F1 --> H
style H fill:#ffcdd2,stroke:#333
- PI3K/Akt: Cell survival, migration, metabolic regulation
- MAPK/ERK: Proliferation, cytokine production, cell differentiation
- PLC/IP3: Calcium mobilization, granule release
- JAK/STAT: Gene transcription, inflammatory response
- Desensitization: GRK-mediated phosphorylation leads to β-arrestin recruitment
- Internalization: Receptor internalization via clathrin-coated pits
- Recycling: Receptor returns to cell surface or is degraded
| Cell Type |
Expression Level |
Function |
| Neutrophils |
Highest |
Primary IL-8 responsive cells |
| Monocytes/Macrophages |
High |
Inflammatory signaling |
| Microglia |
Moderate-high |
CNS immune surveillance |
| T Cells |
Low-moderate |
Chemotactic migration |
| NK Cells |
Moderate |
Cytotoxic activity |
Microglia:
- Resting microglia: Low CXCR1 expression
- Activated microglia: Upregulated CXCR1
- Proximity to amyloid plaques: Elevated expression
Astrocytes:
- Reactive astrocytes: Increased CXCR1
- Inflammatory conditions: Enhanced signaling
Neurons:
- Low baseline expression
- Upregulation in pathological states
- May contribute to excitotoxicity
| Disease State |
CXCR1 Expression |
Significance |
| Alzheimer's Disease |
Increased |
Plaque-associated microglia |
| Parkinson's Disease |
Elevated |
Substantia nigra inflammation |
| Multiple Sclerosis |
Upregulated |
Active lesions |
| Stroke/Ischemia |
Rapidly increased |
Post-injury inflammation |
| ALS |
Elevated |
Motor neuron inflammation |
CXCR1 plays a significant role in AD pathogenesis:
Microglial Activation:
- IL-8 levels are elevated in AD brains and cerebrospinal fluid
- CXCR1+ microglia surround amyloid plaques
- Activation leads to pro-inflammatory cytokine release
- Sustained inflammation contributes to neuronal dysfunction
Neuroinflammation Cascade:
- Amyloid-beta accumulation → IL-8 production by astrocytes/microglia
- IL-8 binding to CXCR1 on microglia → activation
- Pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6)
- Chronic neuroinflammation → synaptic loss, neuronal death
Research Findings:
- CXCR1 expression colocalizes with amyloid plaques
- IL-8/CXCR1 axis amplifies neuroinflammation
- Correlation between CXCR1 and disease severity
In PD, CXCR1 contributes to:
Substantia Nigra Inflammation:
- Elevated IL-8 in PD substantia nigra
- CXCR1 activation on microglia promotes M1 phenotype
- Inflammatory mediators contribute to dopaminergic neuron death
- Neuroinflammation exacerbates alpha-synuclein pathology
Mechanistic Pathways:
- CXCR1 signaling → oxidative stress
- Cytokine release → mitochondrial dysfunction
- Chronic activation → progressive neurodegeneration
- Demyelination: CXCR1+ immune cells contribute to myelin damage
- Lesion Formation: Active MS lesions show elevated CXCR1
- Blood-Brain Barrier Disruption: CXCR1 mediates immune cell trafficking
- Motor Neuron Inflammation: CXCR1 on activated microglia
- Disease Progression: Inflammatory signaling contributes to motor neuron loss
- Therapeutic Target: CXCR1 antagonists under investigation
¶ Stroke and Ischemia
- Post-Ischemic Inflammation: Rapid IL-8 elevation
- Neutrophil Recruitment: CXCR1 mediates post-injury inflammation
- Secondary Damage: Inflammatory cascade exacerbates injury
Several small molecule antagonists have been developed:
| Compound |
Target |
Status |
| Reparixin |
CXCR1/2 |
Clinical trials (pancreatitis, COVID-19) |
| Danirixin |
CXCR2 |
Clinical development |
| SX-517 |
CXCR1 |
Pre-clinical |
| Lidocaine derivatives |
CXCR1/2 |
Investigational |
- Neuroinflammation Modulation: Reduce chronic inflammation
- Microglial Activation: Shift from M1 to M2 phenotype
- Neuroprotection: Prevent inflammatory neuron loss
- Receptor Redundancy: Multiple chemokines can signal through CXCR1/2
- Acute vs Chronic: Different effects in acute vs chronic inflammation
- BBB Penetration: Drug delivery to CNS is challenging
- Small Molecule Inhibitors: Systemic administration
- Monoclonal Antibodies: Target circulating IL-8 or CXCR1
- ASO Therapy: Reduce IL-8 expression
- Gene Therapy: Modulate receptor expression
flowchart TD
A["Pathological Stimulus"] --> B["IL-8 Production"]
B --> C["CXCR1 Activation"]
C --> D["Microglial Activation"]
D --> E["Pro-inflammatory Cytokines"]
E --> F["TNF-α, IL-1β, IL-6"]
F --> G["Chronic Neuroinflammation"]
G --> H["Synaptic Dysfunction"]
G --> I["Neuronal Death"]
H --> J["Neurodegeneration"]
I --> J
style J fill:#ffcdd2,stroke:#333
- Serum IL-8: Elevated in AD and PD
- CSF IL-8: Correlates with disease progression
- CXCR1 Expression: On circulating immune cells
- Imaging: PET ligands for CXCR1 under development
- Expression Analysis: CXCR1 on peripheral monocytes
- Disease Monitoring: IL-8 levels as progression marker
- In Vitro Models: Primary microglia culture
- Animal Models: Transgenic mice, toxin models
- Clinical Trials: CXCR1/2 antagonists in neurodegenerative disease
- Liu et al., CXCR1/2 in neuroinflammation and neurodegeneration (2019)
- Bhatia et al., IL-8 and CXCR1 in AD (2005)
- Glass et al., Inflammation in neurodegeneration (2006)
- Rivest et al., IL-8 signaling in neuroinflammation (2009)
- Horuk et al., IL-8 receptor molecular characterization (1994)
- Wood et al., Chemokine receptors on microglia (2006)
- Galimberti et al., IL-1beta and IL-1RA in AD (2005)
- Zhao et al., CXCR1/2 in PD and neuroinflammation (2018)
- Reaux-Le Goazigo et al., Chemokines in brain (2012)
- Swardfager et al., Meta-analysis of cytokines in AD (2010)
- Lucin & Wyss-Coray, CX3CL1-CX3CR1 in AD (2010)
- Cunningham et al., Systemic inflammation in AD progression (2013)
- White et al., Chemokine signaling in neuropathic pain (2011)
- Tripathy et al., CXCR1/2 antagonists in neuroinflammation (2018)